New page

Ophthalmic Formulation That Improves Stability of Cystinosis Treatments

Technology #17168

Questions about this technology? Ask a Technology Manager

Download Printable PDF

Categories
Researchers
Anuj Chauhan
Phillip J. Dixon
Managed By
Lenny Terry
Assistant Director 352-392-8929
Patent Protection
US Patent Pending

Increases Shelf Life of Cysteamine by Delaying Its Oxidation Rate

This eye-drop formulation can increase the effectiveness of ocular cystinosis treatments by delaying the oxidation rate of cysteamine to increase the shelf life of eye-drop products. Cystinosis is a rare genetic disorder that causes crystalline deposits to accumulate in the cornea, negatively affecting vision. If left untreated, cystinosis can lead to stunted growth, renal failure and blindness. Applying cysteamine eye drops flushes harmful compounds out of eye cells to treat the disease. However, cysteamine drops oxidize when exposed to air, making the drops ineffective a short time after opening the dropper for use. Freezing available cysteamine drop treatments prior to use or sealing them with low-oxygen-permeable materials, such as bromobutyl or aluminum, extends their shelf life. However, neither protects the formulation from air that enters the bottle when administering the drops, making the treatment maximally effective for only about a week after opening. 

Researchers at the University of Florida have developed a formulation to slow the degradation rate of cysteamine. Integrating an oxygen-resistant polymer to the formulation combined with floating a hydrophobic antioxidant layer on its surface increases the shelf life of available cysteamine drop treatments to nearly a month after opening. 



Application
Formulation to increase the shelf life of available cysteamine treatments for ocular cystinosis    

Advantages

• Improves the chemical stability of commercially available cysteamine, extending usage to roughly one-month
• Combines the addition of a hydrophobic floating layer and an oxygen-resistant polymer, delaying degradation with a two-fold approach
 

Technology
A hydrophobic oil added to cysteamine prevents oxidation of the cysteamine’s thiol group. The oil impedes the rate of completion for the redox reaction between oxygen molecules and the compound’s active ingredient, which slows the oxidation process. An inorganic polymer present in the eye drop bottle works in conjunction with this protective barrier, increasing the solution’s viscosity. The polymer also prolongs contact with the cornea once the formulation enters the eye, increasing bioavailability of non-degraded cysteamine.

Return to the main UF Innovate | Tech Licensing site here